胎儿水肿:外显子测序较标准产前诊断的增量产出研究
这项前瞻性队列研究联合系统综述与meta分析,评估染色体微阵列分析或核型分析阴性后,外显子测序在产前诊断的非免疫性胎儿水肿中的额外诊断产出。扩展PAGE队列28例中额外产出25.0%,meta分析21项研究306例的合并额外产出为29%(95%CI 24-34%),孤立性水肿21%,合并其他结构异常者39%,提示应考虑将产前二代测序纳入临床路径。
要点
- CMA或核型阴性后,外显子测序在非免疫性胎儿水肿中仍有约29%的额外诊断产出
- 合并其他结构异常的水肿额外产出更高(39%),孤立性水肿为21%
- 最常见遗传病为RASopathies,占致病性变异病例的30.3%
核心结论
- 在产前诊断的非免疫性胎儿水肿中,CMA或核型分析阴性后外显子测序的合并额外诊断产出为29%(95%CI 24-34%)。
- 孤立性水肿与合并其他结构异常的水肿额外产出分别为21%(95%CI 13-30%)和39%(95%CI 30-49%),后者更高。
- 外显子或全基因组测序可能比靶向基因panel更适合水肿的产前遗传学检测。
研究设计与样本
- 前瞻性队列研究(PAGE研究扩展组),纳入28例产前诊断的非免疫性胎儿水肿,CMA或核型阴性后行三联体外显子测序。
- 联合系统综述与meta分析,检索MEDLINE、EMBASE、CINAHL和ClinicalTrials.gov(2000年1月至2020年10月)。
- meta分析纳入21项研究共306例,参考标准为CMA或核型分析阴性。
关键影像表现/征象
- 非免疫性胎儿水肿可伴发先天性肢体挛缩,为最常见的相关附加结构异常,占110例中的17.3%(19/110)。
- 导致水肿的致病性变异以RASopathies最常见,占89例致病性变异病例的30.3%(27/89),其中PTPN11变异占44.4%(12/27)。
诊断标准与关键数值
- 扩展PAGE队列中,外显子测序较CMA或核型的额外诊断产出:全部水肿25.0%(7/28),孤立性水肿21.4%(3/14),非孤立性水肿28.6%(4/14)。
- meta分析合并额外产出:全部水肿29%(95%CI 24-34%;P<0.00001;I2=0%),孤立性水肿21%(95%CI 13-30%;P<0.00001;I2=0%),合并其他结构异常的水肿39%(95%CI 30-49%;P<0.00001;I2=1%)。
- 额外诊断产出按水肿严重程度(累及两个 vs 三个或以上腔隙)无显著差异。
临床应用与阅片要点
- 对CMA或核型阴性的非免疫性胎儿水肿,无论孤立与否,均应考虑产前外显子或全基因组测序以明确遗传病因。
- 合并其他结构异常(尤其肢体挛缩)的水肿,遗传学检测的阳性产出更高,应积极建议测序。
- RASopathies是水肿的重要遗传病因,报告时应结合基因变异提示相关综合征可能。
局限性
- 扩展队列样本量较小(28例),孤立性与非孤立性亚组各14例,估计值不稳定。
- meta分析纳入研究间水肿表型定义和测序策略可能存在异质性。
- 系统综述仅纳入已发表研究,可能存在发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the incremental yield of exome sequencing (ES) over chromosomal microarray analysis (CMA) or karyotyping in prenatally diagnosed non-immune hydrops fetalis (NIHF).
METHODS: A prospective cohort study (comprising an extended group of the Prenatal Assessment of Genomes and Exomes (PAGE) study) was performed which included 28 cases of prenatally diagnosed NIHF undergoing trio ES following negative CMA or karyotyping. These cases were combined with data from a systematic review of the literature. MEDLINE, EMBASE, CINAHL and ClinicalTrials.gov databases were searched electronically (January 2000 to October 2020) for studies reporting on the incremental yield of ES over CMA or karyotyping in fetuses with prenatally detected NIHF. Inclusion criteria for the systematic review were: (i) at least two cases of NIHF undergoing sequencing; (ii) testing initiated based on prenatal ultrasound-based phenotype; and (iii) negative CMA or karyotyping result. The incremental diagnostic yield of ES was assessed in: (i) all cases of NIHF; (ii) isolated NIHF; (iii) NIHF associated with an additional fetal structural anomaly; and (iv) NIHF according to severity (i.e. two vs three or more cavities affected).
RESULTS: In the extended PAGE study cohort, the additional diagnostic yield of ES over CMA or karyotyping was 25.0% (7/28) in all NIHF cases, 21.4% (3/14) in those with isolated NIHF and 28.6% (4/14) in those with non-isolated NIHF. In the meta-analysis, the pooled incremental yield based on 21 studies (306 cases) was 29% (95% CI, 24-34%; P < 0.00001; I2 = 0%) in all NIHF, 21% (95% CI, 13-30%; P < 0.00001; I2 = 0%) in isolated NIHF and 39% (95% CI, 30-49%; P < 0.00001; I2 = 1%) in NIHF associated with an additional fetal structural anomaly. In the latter group, congenital limb contractures were the most prevalent additional structural anomaly associated with a causative pathogenic variant, occurring in 17.3% (19/110) of cases. The incremental yield did not differ significantly according to hydrops severity. The most common genetic disorders identified were RASopathies, occurring in 30.3% (27/89) of cases with a causative pathogenic variant, most frequently due to a PTPN11 variant (44.4%; 12/27). The predominant inheritance pattern in causative pathogenic variants was autosomal dominant in monoallelic disease genes (57.3%; 51/89), with most being de novo (86.3%; 44/51).
CONCLUSIONS: Use of prenatal next-generation sequencing in both isolated and non-isolated NIHF should be considered in the development of clinical pathways. Given the wide range of potential syndromic diagnoses and heterogeneity in the prenatal phenotype of NIHF, exome or whole-genome sequencing may prove to be a more appropriate testing approach than a targeted gene panel testing strategy. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Mone F, Eberhardt RY, Hurles ME, et al. Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis. Ultrasound Obstet Gynecol. 2021. PMID: 33847422. doi:10.1002/uog.23652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。